Federal biotech ban targets foreign genetic-data collection—but OMB gets broad power to expand it

What it does

This bill prohibits federal agencies and federal-grant recipients from buying biotechnology equipment or services from companies deemed a national security threat—primarily Chinese military-linked firms and foreign-government-controlled entities engaged in genetic data collection. It requires the OMB to publish a list of banned companies within one year, with 60–90 day implementation windows, and allows case-by-case waivers for national security or overseas health care. The bill aims to prevent foreign adversaries from acquiring Americans' genetic and biological data through commercial biotech channels.

Why we flagged it

The bill's operative mechanism is a procurement ban targeting foreign-government-controlled biotech firms. It is not a subsidy, tax carve-out, or deregulation—it is a targeted restriction on federal spending to protect genetic privacy and national security.

What the text implies

• The OMB's discretion to define 'biotechnology equipment or service' broadly (subsection k(2)(C)) gives executive branch significant power to expand the ban beyond genetic sequencers to any biotech tool deemed a national security risk, potentially affecting legitimate research partnerships.
• The 90-day review and removal process (subsection f(7)) may be insufficient for companies to challenge designations if the underlying intelligence is classified and cannot be disclosed, creating a due-process gap.
• Subsidiaries and successors of banned companies are automatically banned if they meet criteria (subsection f(2)(C)), potentially trapping legitimate spin-offs or acquired entities in the restriction even if they have no connection to the parent's conduct.
• The exception for 'lawfully compiled' multiomic data that is 'commercially or publicly available' (subsection e(3)) may not prevent foreign adversaries from purchasing genetic data on the open market, limiting the bill's practical effect on data collection.
• Overseas health care waivers (subsection d(2)) create a carve-out that could allow federal contractors to use banned biotech services abroad, potentially circumventing the ban's intent if the same data flows back to foreign governments.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill protects Americans' genetic privacy and national security by blocking federal funds from flowing to foreign-controlled biotech firms that collect and share genetic data with hostile governments. Citizens gain a concrete protection: their tax dollars cannot fund the collection and transfer of their biological data to foreign adversaries. The waiver provisions and exceptions for legitimate overseas health care preserve necessary government functions.

Who stands to gain

• U.S. biotechnology companies not on the banned list (gain competitive advantage by excluding foreign
• Domestic genetic sequencing and multiomic data service providers (increased federal procurement dema

Named in the bill

Office of Management and Budget (OMB), Department of Defense (DoD), Director of National Intelligence (DNI), Secretary of Health and Human Services (HHS), Secretary of Commerce, Secretary of Homeland Security (DHS), Secretary of State, National Cyber Director, Attorney General, Federal Acquisition Regulatory Council, Committee on Homeland Security and Governmental Affairs (Senate), Committee on Oversight and Government Reform (House) — and 1 more

Where it stands

1 cosponsor: 1 Republicans.

• Dec 11, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Dec 11, 2025 — Referred to Senate Committee on Homeland Security and Governmental Affairs · Congress.gov: “Read twice and referred to the Committee on Homeland Security and Governmental Affairs”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $870,000 in lobbying spend. A filing names 21 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Gary Peters, the sponsor, reported $-186,100 in PAC receipts in the 2026 cycle.

• Association for Accessible Medicines — $870,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.